Prevalence of primary immune thrombocytopenia in Oklahoma

被引:70
作者
Terrell, Deirdra R. [1 ]
Beebe, Laura A. [1 ]
Neas, Barbara R. [1 ]
Vesely, Sara K. [1 ]
Segal, Jodi B. [2 ]
George, James N. [1 ,3 ]
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Biostat & Epidemiol, Oklahoma City, OK 73126 USA
[2] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[3] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Med, Oklahoma City, OK 73126 USA
关键词
QUALITY-OF-LIFE; PURPURA; ADULTS; CHILDHOOD; CHILDREN; PATIENT;
D O I
10.1002/ajh.23262
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To determine the prevalence of immune thrombocytopenia (ITP) in Oklahoma regardless of age, clinical characteristics, insurance status, and source of health care. Patients with ITP were identified by the administrative code ICD-9-CM 287.3 in Oklahoma hematologists' offices for a 2-year period, 20032004. Prevalence was estimated separately for children (<16 years old) and adults because of their distinct clinical characteristics. Oklahoma census data for 2000 was used as the denominator. Eighty-seven (94%) of 93 eligible Oklahoma hematologists participated; 620 patients with ITP were identified. The average annual prevalences were as follows: 8.1 (95% CI: 6.79.5) per 100,000 children, 12.1 (95% CI: 11.113.0) per 100,000 adults, and 11.2 (95% CI: 10.412.0) per 100,000 population. Among children and adults less than age 70 years, the prevalence was greater among women. Among adults aged 70 years and older, the prevalence was greater among men. The highest prevalence of ITP was among men age 80 years and older. These data document for the first time the prevalence of ITP regardless of age, clinical characteristics, insurance status, and source of health care. The methodology developed for this prevalence analysis may be adaptable for epidemiologic studies of other uncommon disorders which lack specific diagnostic criteria and are treated primarily by medical specialists. Am. J. Hematol. 2012. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:848 / 852
页数:5
相关论文
共 28 条
[1]   The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review [J].
Abrahamson, Page E. ;
Hall, Susan A. ;
Feudjo-Tepie, Maurille ;
Mitrani-Gold, Fanny S. ;
Logie, John .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 83 (02) :83-89
[2]  
[Anonymous], 2001, CENS FACTF
[3]   Prevalence of Diagnosed Adult Immune Thrombocytopenia in the United Kingdom [J].
Bennett, Dimitri ;
Hodgson, M. Elizabeth ;
Shukla, Amit ;
Logie, John W. .
ADVANCES IN THERAPY, 2011, 28 (12) :1096-1104
[4]   Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal [J].
Feudjo-Tepie, M. A. ;
Robinson, N. J. ;
Bennett, D. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (04) :711-712
[5]   The incidence of idiopathic thrombocytopenic purpura in adults increases with age [J].
Frederiksen, H ;
Schmidt, K .
BLOOD, 1999, 94 (03) :909-913
[6]   Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus [J].
George, James N. ;
Vesely, Sara K. ;
James, Judith A. .
SOUTHERN MEDICAL JOURNAL, 2007, 100 (05) :512-514
[7]   Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials [J].
George, James N. ;
Mathias, Susan D. ;
Go, Ronald S. ;
Guo, Matthew ;
Henry, David H. ;
Lyons, Roger ;
Redner, Robert L. ;
Rice, Lawrence ;
Schipperus, Martin R. .
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (03) :409-415
[8]   Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives [J].
Guidry, Jacqueline A. ;
George, James N. ;
Vesely, Sara K. ;
Kennison, Shelia M. ;
Terrell, Deirdra R. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 83 (03) :175-182
[9]   Prevalence and treatment of chronic idiopathic thrombocytopenic purpura of childhood in Sweden [J].
Hedman, A ;
Henter, JI ;
Hedlund, I ;
Elinder, G .
ACTA PAEDIATRICA, 1997, 86 (02) :226-227
[10]  
Imbach P, 2005, PEDIAT BLOOD CANC, P1